The U.S. Department of Justice has formally accused Done Global of unlawfully distributing ADHD medications without medical need, using a subscription program and targeted advertising to find patients searching for drugs. The company is also accused of filing false medical claims to Medicare, Medicaid and commercial insurance. Done's founder and CEO was convicted last month on related charges and awaits sentencing. 

The biggest investor in a nursing home chain can run but not hide from comeuppance for the chain’s alleged role in harms—including deaths—done to hundreds of patients.

An exclusive report from local NBC affiliate KARE 11 tells the story of Noah Leopold, a man who died after receiving two new hearts. The first deteriorated, and the second one killed him. Now, his family is suing, saying the Mayo Clinic failed to inform them of the risks. The nonprofit health system denies the allegations. 

Peak AI hype seems to have passed. Sobered by reality, formerly breathless futurists can now get a fair hearing when they calmly state the technology really will transform medicine. 

In total, 22 facilities will benefit from the money, provided by the Statewide Health Care Facility Transformation Program. Projects include cybersecurity upgrades and telehealth implementation, in addition to EHR upgrades.

By signing an executive order, President Donald Trump has shifted marijuana from a Schedule I to a Schedule III controlled substance, opening the door for medical and research uses nationwide. 

A Hail Mary attempt by a bipartisan group to extend Affordable Care Act tax credits failed. The new bill contains some reforms, including new reporting requirements for PBMs and support for association health plans. It now faces the Senate. 

Authorities allege the pharmacy chain gave patients more insulin than prescribed and then billed Medicare and Medicaid for the full amounts. This allegedly occurred for more than a decade. 

A psychiatric patient suffering from hallucinations injured employees at University of Iowa Health Care during a physical altercation. Clinicians restrained and sedated him successfully, but the cocktail of drugs allegedly caused his heart to stop, leading to a permanent brain injury. The case has been settled out of court.

Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo. 

Founded in 2023, Hunterbrook is an investigative news and investment outlet, which creates reports criticizing publicly traded companies and then benefits from the corresponding drop in share prices